UO Immunoterapia e laboratorio TCS, IRST IRCCS
Welcome,         Profile    Billing    Logout  
 6 Trials 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Guidoboni, Massimo
KEYNOTE-D18, NCT05155254 / 2021-004594-32: IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

Active, not recruiting
3
407
Europe, US, RoW
IO102-IO103, Pembrolizumab
IO Biotech, Syneos Health, Merck Sharp & Dohme LLC
Metastatic Melanoma, Unresectable Melanoma
07/25
09/27
ABSIDE, NCT01973322 / 2012-001410-41: Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized "Proof-of-principle" Phase II Study

Completed
2
34
Europe
arm 1: DC Vaccine + RT, vaccine + radiotherapy, arm 2: DC Vaccine + IFN-alfa, vaccine + drug, arm 3: both arm 1 and 2 + RT, vaccine + radiotherapy + drug, arm 4: DC Vaccine, vaccine
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Malignant Melanoma of Skin Stage III, Malignant Melanoma of Skin Stage IV
09/23
06/24
NCT05299580 / 2019-004760-21: "Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"

Withdrawn
2
35
Europe
dabrafenib, Trametinib
Fondazione Melanoma Onlus, Novartis Farma S.p.A.
Melanoma
03/23
03/23
NCT05529316: A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

Active, not recruiting
2
220
Europe, US, RoW
Botensilimab, AGEN1181, Balstilimab, AGEN2034
Agenus Inc.
Advanced Melanoma
05/28
05/28
NEO-TIM, NCT04722575 / 2018-004841-17: Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma

Active, not recruiting
2
95
Europe
Cobimetinib 20 MG Oral Tablet, Cotellic, Vemurafenib 240 Mg Oral Capsule, Zelboraf, Atezolizumab 1200 MG in 20 ML Injection, Tecentriq
Fondazione Melanoma Onlus, Clinical Research Technology S.r.l.
Melanoma
12/23
06/27
MESOVAX, NCT03546426: Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies

Active, not recruiting
1
18
Europe
Pembrolizumab, Autologous dendritic cells, Interleukin-2
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Mesothelioma, Malignant, PD-L1 Negative, Advanced Cancer, Progressive Disease
01/27
09/28
NCT04759846: Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma

Withdrawn
1
12
Europe, RoW
Encorafenib + Binimetinib, Braftovi + Mektovi
Pierre Fabre Medicament
BRAF V600 Mutation, Unresectable Melanoma, Metastatic Melanoma, Hepatic Impairment
05/23
05/23

Download Options